USANA Health Sciences financials
$14.70−0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jul 4 | Q1 '26 Apr 4 | Q4 '25 Jan 3 | Q3 '25 Sep 27 | Q2 '25 Jun 28 | Q1 '25 Mar 29 | Q4 '24 Dec 28 | Q3 '24 Sep 28 | Q2 '24 Jun 29 | Q1 '24 Mar 30 | Q4 '23 Dec 30 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $223.3M | $250.2M | $226.2M | $213.7M | $235.8M | $249.5M | $213.6M | $200.2M | $212.9M | $227.8M | $221.1M | $213.4M |
| Gross profit | $174.9M | $190.8M | $176.8M | $164.9M | $185.7M | $197.1M | $175.1M | $161.0M | $172.5M | $184.7M | $178.8M | $170.8M |
| Gross margin | 78.3% | 76.2% | 78.2% | 77.2% | 78.7% | 79.0% | 82.0% | 80.4% | 81.1% | 81.1% | 80.9% | 80.1% |
| Operating income | $9.1M | $13.9M | $3.8M | $1.2M | $16.7M | $15.7M | $8.2M | $15.6M | $17.8M | $24.7M | $24.2M | $17.6M |
| Net income | -$21.4M | $7.5M | -$1.8M | -$6.5M | $9.7M | $9.4M | $4.5M | $10.6M | $10.4M | $16.5M | $16.8M | $11.3M |
| Net margin | −9.6% | 3.0% | −0.8% | −3.1% | 4.1% | 3.8% | 2.1% | 5.3% | 4.9% | 7.3% | 7.6% | 5.3% |
| Diluted EPS | $-1.16 | $0.41 | $-0.10 | $-0.36 | $0.52 | $0.49 | $0.23 | $0.56 | $0.54 | $0.86 | $0.87 | $0.59 |
| EBITDA | $16.8M | $22.2M | $25.8M | $9.1M | $24.5M | $24.0M | $12.2M | $19.2M | $21.7M | $27.8M | $24.2M | $20.9M |
| Operating cash flow | $23.3M | $9.8M | -$3.4M | -$2.0M | $12.2M | $15.5M | $5.8M | $29.5M | $8.0M | $17.7M | $26.0M | $22.2M |
| Free cash flow | $20.2M | $7.1M | -$6.2M | -$5.2M | $7.2M | $12.7M | $4.0M | $27.1M | $5.3M | $14.5M | $18.7M | $20.8M |
| Diluted shares | 18.5M | 18.4M | 18.4M | 18.3M | 18.5M | 19.1M | 19.1M | 19.1M | 19.2M | 19.3M | 19.3M | 19.4M |
Balance sheet
| Period end | Jul 4 | Apr 4 | Jan 3 | Sep 27 | Jun 28 | Mar 29 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $168.6M | $162.8M | $158.4M | $145.3M | $151.3M | $179.6M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $14.0M | $14.0M | $0.00 | $0.00 | $23.0M |
| Total assets | $703.2M | $739.0M | $742.9M | $726.6M | $734.5M | $746.6M |
| Total liabilities | $132.2M | $144.2M | $156.6M | $145.0M | $149.0M | $162.7M |
| Shareholders' equity | $571.0M | $543.5M | $586.3M | $528.1M | $531.1M | $529.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology